EMA Authorised: Dificlir (fidaxomicin) — Tillotts Pharma GmbH

View source ↗

Summary

The European Medicines Agency authorised Dificlir (fidaxomicin) for Clostridioides difficile infection, with Tillotts Pharma GmbH as the marketing authorization…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Dificlir (fidaxomicin)

Snippet

Status: Authorised. Therapeutic area: Clostridium Infections. MAH: Tillotts Pharma GmbH. Decision date: 01/12/2023